

## Article

**mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype**

Nicolás Herranz<sup>1,2</sup>, Suchira Gallage<sup>1,2,3</sup>, Massimiliano Mellone<sup>4</sup>, Torsten Wuestefeld<sup>5, a</sup>, Sabrina Klotz<sup>5</sup>, Christopher J. Hanley<sup>4</sup>, Selina Raguz<sup>1,2</sup>, Juan Carlos Acosta<sup>1,2</sup>, Andrew J Innes<sup>1,2</sup>, Ana Banito<sup>1,2</sup>, Athena Georgilis<sup>1,2</sup>, Alex Montoya<sup>6</sup>, Katharina Wolter<sup>5</sup>, Gopuraja Dharmalingam<sup>2</sup>, Peter Faull<sup>6</sup>, Thomas Carroll<sup>2</sup>, Juan Pedro Martínez-Barbera<sup>7</sup>, Pedro Cutillas<sup>6, b</sup>, Florian Reisinger<sup>8</sup>, Mathias Heikenwalder<sup>8,9</sup>, Richard A. Miller<sup>10</sup>, Dominic Withers<sup>3</sup>, Lars Zender<sup>5</sup>, Gareth J. Thomas<sup>4</sup>, and Jesús Gil<sup>1, 2, \*</sup>

<sup>1</sup>Cell Proliferation Group, <sup>2</sup>Epigenetics Section, <sup>3</sup>Metabolic Signalling Group, and <sup>6</sup>Proteomics Facility; MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London W12 0NN, UK.

<sup>4</sup>Cancer Sciences Unit, Cancer Research UK Centre, Somers Building, University of Southampton, Southampton SO16 6YD, UK.

<sup>5</sup>Division of Molecular Oncology of Solid Tumors, Dept. of Internal Medicine I, Eberhard Karls University Tübingen, 72076 Tübingen, Germany.

<sup>7</sup>Birth Defects Research Centre, Neural Development Unit, UCL Institute of Child Health, London, WC1N 1EH, UK

<sup>8</sup>Institute for Virology, Technische Universität München/Helmholtz Zentrum München, Munich, Germany.

<sup>9</sup>Division of Chronic Inflammation and Cancer, German Cancer Research (DKFZ), Heidelberg, Germany.

<sup>10</sup>Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, MI 48109-2200, USA

<sup>a</sup>Current address: Stem Cell & Regenerative Biology, Genome Institute of Singapore, Singapore 138672

<sup>b</sup>Current address: Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ

\*Corresponding author: [jesus.gil@csc.mrc.ac.uk](mailto:jesus.gil@csc.mrc.ac.uk)

**Short title:** mTOR controls the SASP

**Keywords:** mTOR, SASP, senescence, rapamycin, MAPKAPK2, ZFP36L1.

**ABSTRACT**

Senescent cells secrete a combination of factors collectively known as the senescence-associated secretory phenotype (SASP). The SASP reinforces senescence and activates an immune surveillance response but it can also display pro-tumorigenic properties and contribute to age-related pathologies. In a drug screen to find novel SASP regulators, we uncovered the mTOR inhibitor rapamycin as a potent SASP suppressor. Here we report a mechanism by which mTOR controls the SASP by differentially regulating the translation of the MK2/MAPKAPK2 kinase through 4EBP1. In turn, MAPKAPK2 phosphorylates the RNA binding protein ZFP36L1 during senescence, inhibiting its ability to degrade the transcripts of numerous SASP components. Consequently, mTOR inhibition or constitutive activation of ZFP36L1 impairs the non-cell-autonomous effects of senescent cells both in tumour-suppressive and promoting-promoting contexts. Altogether, our results place regulation of the SASP as a key mechanism by which mTOR could influence cancer, age-related diseases and immune responses.